Intangible assets
The carrying amount of intangible assets mainly comprises goodwill on the acquisition of NeoResins in 2005 (€358 million), Crina in 2006 (€8 million) and Pentapharm in 2007 (€33 million). For further information on these assets including the discussion of the related impairment tests, please refer to Note 8 'Intangible assets' in the 'Notes to the consolidated financial statements of Royal DSM'.
Goodwill | Under construction | Other | Total | |
Balance at 1 January 2016 | ||||
|---|---|---|---|---|
Cost | 403 | 17 | 62 | 482 |
Amortization and impairment losses | - | - | 32 | 32 |
Carrying amount | 403 | 17 | 30 | 450 |
Change in carrying amount | ||||
- Capital expenditure | - | 3 | - | 3 |
- Put into operation | - | (16) | 16 | - |
- Amortization | - | - | (6) | (6) |
- | (13) | 10 | (3) | |
Balance at 31 December 2016 | ||||
Cost | 403 | 4 | 78 | 485 |
Amortization and impairment losses | - | - | 38 | 38 |
Carrying amount | 403 | 4 | 40 | 447 |
Change in carrying amount | ||||
- Capital expenditure | - | 1 | - | 1 |
- Put into operation | - | (4) | 4 | - |
- Exchange difference | (4) | - | - | (4) |
- Amortization | - | - | (8) | (8) |
- Impairment losses | - | - | (3) | (3) |
(4) | (3) | (7) | (14) | |
Balance at 31 December 2017 | ||||
Cost | 399 | 1 | 83 | 483 |
Amortization and impairment losses | - | - | 50 | 50 |
Carrying amount | 399 | 1 | 33 | 433 |